ResearchIDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy
ResearchZiftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia
ResearchDifferential responses to sequential menin inhibitor therapy for acute leukemia underscore the complexities of acquired resistance
ResearchOPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML
ResearchRisk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model
ResearchSignaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA
ResearchTamibarotene with venetoclax and azacitidine in RARA(+) acute myeloid leukemia: results from the SY-1425-202 study